0001104659-23-089937.txt : 20230810
0001104659-23-089937.hdr.sgml : 20230810
20230810184906
ACCESSION NUMBER: 0001104659-23-089937
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230808
FILED AS OF DATE: 20230810
DATE AS OF CHANGE: 20230810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bastone Bronwen
CENTRAL INDEX KEY: 0001927636
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40949
FILM NUMBER: 231161064
MAIL ADDRESS:
STREET 1: C/O ENFUSION, INC.
STREET 2: 125 SOUTH CLARK STREET SUITE 750
CITY: CHICAGO
STATE: IL
ZIP: 60603
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Enfusion, Inc.
CENTRAL INDEX KEY: 0001868912
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 125 SOUTH CLARK STREET, SUITE 750
CITY: CHICAGO
STATE: IL
ZIP: 60603
BUSINESS PHONE: (312) 253-9800
MAIL ADDRESS:
STREET 1: 125 SOUTH CLARK STREET, SUITE 750
CITY: CHICAGO
STATE: IL
ZIP: 60603
4
1
tm2323475-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-08-08
0
0001868912
Enfusion, Inc.
ENFN
0001927636
Bastone Bronwen
C/O ENFUSION, INC.
125 SOUTH CLARK STREET SUITE 750
CHICAGO
IL
60603
0
1
0
0
Chief People Officer
0
Class A Common Stock
2023-08-08
4
A
0
153
0
A
156657
D
Class A Common Stock
2023-08-09
4
S
0
55
8.32
D
156602
D
Consists of fully vested shares issued under the Enfusion, Inc. 2021 Stock Option and Incentive Plan in connection with the previously disclosed pre-IPO termination of the Enfusion Ltd. LLC Change in Control Bonus Plan (the "Shares").
Consists of shares required by the Issuer to be sold by the Reporting Person to cover tax withholding obligations in connection with the issuance of the Shares, and does not represent discretionary trades by the Reporting Person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.48. Full information regarding the number of shares sold at each separate price will be furnished to the SEC staff upon request.
/s/ Matthew Campobasso, as Attorney-in-Fact
2023-08-10